Union Investment Partners
VC Fund
Seoul, South Korea
Union Investment Partners is a VC fund in Seoul focused on Biotechnology and Health Care. “Union Investment Partners” since its founding in 2000, has been the leading venture capital firm in Korea specializing in contents investment that includes successful investment portfolios of films, animations, games, TV dramas, and live concerts. Union Investment Partners will maintain its role as a major investment partner of venture businessesand contents industry that seeks growth and advancement to the global market.
- Total investments:
- 59
- Last investment:
- Lead investor:
- 10%
Last updated:
For AI agents: llms.txt
Industries Union Investment Partners invests in
Stages Union Investment Partners invests in
Countries Union Investment Partners invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $1.5M–$8.6M
- Series B
- $4.2M–$18M
Investment Focus
Industry
- Biotechnology 8 (14%)
- Health Care 5 (8%)
- Media and Entertainment 5 (8%)
- Gaming 4 (7%)
- Medical 4 (7%)
Stage
- Series A 19 (32%)
- Series B 12 (20%)
- Venture - Series Unknown 11 (19%)
- Seed 10 (17%)
- Series C 4 (7%)
Country
- South Korea 48 (81%)
- United States 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Jaewoo Lee
Chief Executive Officer
|
Chief Executive Officer | Total investments: 0 | Find email | |
|
Kim Taek-gyun
Vice President & Chief Operating Officer
|
Vice President & Chief Operating Officer | Total investments: 0 | Find email | |
|
Paul Young-Do Kim
Managing Director
|
Managing Director | Total investments: 2 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Awexome Ray is a company that manufactures next-generation X-ray generator. | $5.3M / Series B / Aug 10, 2026 | ||
| LabInCube develops inCube materials capable of selective drug release, sustained release, and supporting complex raw materials. | $9.8M / Series B / Mar 18, 2026 | ||
| Pinot Bio is a biotechnology company that specializes in developing new generation anticancer treatments. | $9.1M / Oct 27, 2025 | ||
| MediMabBio platform uses systems biology combined with sophisticated immunological solutions to identify significantly improving immuno-oncology drugs that can actively target a range of solid tumors. The antibody discovery I-O platform brings the advantages of rational drug design to large molecule therapeutic development. | $17.8M / Series B / Oct 24, 2025 | ||
| Dexter Studios is a total contents production company that can develop and produce variable motion pictures and TV contents, and also, provide state-of-the-art visual effects from the Asia’s largest visual effects production. | $9.5M / Debt Financing / Oct 02, 2025 | ||
| SCBIO is a pharmaceutical company that makes drugs with specialized technologies in immuno-oncology. The company discovers and develops novel therapeutics for future medicine. | $10M / Seed / Sep 01, 2025 | ||
| S2 ENTERTAINMENT is an entertainment management company. It helps K-pop bands and artistes expand worldwide. It manages K-pop artists and produces Korea music. It coordinates artiste activities and fan engagement. | $3.6M / Series A / Jul 30, 2025 | ||
| NearSolution is an AI logistics technology business that provides innovative, cloud-based software solutions for intelligent warehouse execution and logistics optimization. | $2.6M / Series A / Jul 03, 2025 | ||
Livotech
|
Livotech develops drugs that provide treatment for various diseases. The company develops drugs that can treat different diseases using messenger ribonucleic acid targets, enabling doctors to treat genetic diseases by giving patients the correct version of a defective gene. | $1.7M / Seed / Jan 31, 2025 | |
| Ubix Therapeutics is a research and development company that develops anti-cancer drugs. | $17.7M / Series C / Dec 23, 2024 | ||
| See all 59 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Union Investment Partners invest in?
Union Investment Partners invests primarily in Biotechnology, Health Care and Media and Entertainment startups, most often at Series A and Series B stage. Most of the 59 investments tracked by Shizune back companies in South Korea. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Union Investment Partners's check size?
Union Investment Partners typically joins rounds of $1.5M–$8.6M at Series A and $4.2M–$18M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Union Investment Partners participates in.
How do I contact Union Investment Partners?
Public channels for Union Investment Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Union Investment Partners?
The team at Union Investment Partners includes Jaewoo Lee (Chief Executive Officer), Kim Taek-gyun (Vice President & Chief Operating Officer) and Paul Young-Do Kim (Managing Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
